References
- Altman RD. (2010). New guidelines for topical NSAIDs in the osteoarthritis treatment paradigm. Curr Med Res Opin 26:2871–6
- Arsenijevic L, Arsenijevic V, Horeau A, Jacques J. (1988). Synthesis of 2-acetyl-6-methoxynaphthalene. Org Syn 6:34–6
- Cheong HA, Choi HK. (2002). Enhanced percutaneous absoption of piroxicam via salt formation with ethanolamines. Pharm Res 19:1375–80
- Davies NM. (1997). Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet 33:404–16
- Evans JM, McMahon AD, McGilchrist MM, et al. (1995a). Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 311:22–6
- Evans JM, McGregor E, McMahon AD, et al. (1995b). Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM 88:551–7
- Fang L, Numajiri S, Kobayashi D, Morimoto Y. (2003). The use of complexation with alkanolamines to facilitate skin permeation of mefenamic acid. Int J Pharm 262:13–22
- Friedel HA, Langtry HD, Buckley MM. (1993). Nabumetone: a reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 45:131–56
- Furniss BS, Hannaford JH, Smith PWG, Tachell AR. (1996). Vogel’s text book of practical organic chemistry, 5th edition. Singapore: Longman, 987–1054
- Gerard C, Mazzenga B. (1991). The transdermal delivery of zwitterionic drugs I: the solubility of zwitterion salts. J Control Rel 16:77–88
- Ki HM, Choi HK. (2007). The effect of meloxicam/ethanolamine salt formation on percutaneous absorption of meloxicam. Arch Pharm Res 30:215–21
- Komatsu T, Sakurada T. (2012). Comparision of the efficacy and skin permeability of topical NSAID preparations used in Europe. Eur J Pharm Sci 18:890–5
- Lee CM, Maibach HI. (2006). Deep percutaneous penetration into muscles and joints. J Pharm Sci 95:1405–13
- Motsko SP, Rascati KL, Busti AJ, et al. (2006). Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 29:621–32
- Menassé R, Hedwall PR, Kraetz J, et al. (1978). Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol 22:5–16
- Rautio J, Nevalainen T, Taipale H, et al. (2000). Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur J Pharm Sci 11:157–63
- Roberts MS, Cross SE. (1999). Percutaneous absorption of topically applied NSAIDs and other compounds: role of solute properties, skin physiology and delivery system. Inflammopharmacology 7:339–50
- Singh S, Singh J. (1993). Transdermal drug delivery by passive diffusion and iontophoresis: a review. Med Res Rev 13:569–621
- Singh P, Roberts MS. (1994). Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther 268:144–51
- Suh H, Jun HW, Dzimianski MT, Lu GW. (1997). Pharmacokinetic and local tissue disposition studies of naproxen following topical and systemic administration in dogs and rats. Biopharm Drug Disp 18:623–33
- Yano T, Nakawaga A, Tsuji M, Noda K. (1986). Skin permeability of various non-steroidal anti-inflammatory drugs in man. Life Sci 39:1043–50